Effects of FGF21-secreting adipose-derived stem cells in thioacetamide-induced hepatic fibrosis

Journal of Cellular and Molecular Medicine
Hwansu KangHee-Sook Jun

Abstract

Mesenchymal stem cells (MSCs) have been investigated to treat liver diseases, but the efficiency of MSCs to treat chronic liver diseases is conflicting. FGF21 can reduce inflammation and fibrosis. We established FGF21-secreting adipose derived stem cells (FGF21_ADSCs) to enhance the effects of ADSCs and transplanted them into thioacetamide (TAA)-induced liver fibrosis mice via the tail vein. Transplantation of FGF21_ADSCs significantly improved liver fibrosis by decreasing serum hyaluronic acid and reducing the expression of fibrosis-related factors such as α-smooth muscle actin (α-SMA), collagen and tissue inhibitor of metalloproteinase-1 (TIMP-1) compared with the Empty_ADSCs by inhibition of p-JNK, NF-κB and p-Smad2/3 signalling. α-lactoalbumin (LA) and lactotransferrin (LTF), secretory factors produced from FGF21_ADSCs inhibited TGF-β1-induced expression of α-SMA and collagen in LX-2 cells. These results suggest that transplantation of FGF21_ADSCs inhibited liver fibrosis more effectively than Empty_ADSCs, possibly via secretion of α-LA and LTF.

References

May 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yutaka YataDon C Rockey
Feb 4, 2005·The Journal of Clinical Investigation·Ramón Bataller, David A Brenner
Jun 23, 2009·Proceedings of the National Academy of Sciences of the United States of America·Matthew J PotthoffShawn C Burgess
Oct 19, 2011·Cell and Tissue Research·Steven Dooley, Peter ten Dijke
Jan 8, 2013·Pflügers Archiv : European journal of physiology·Claus Hellerbrand
Jul 23, 2014·International Journal of Oncology·Katsunori YoshidaKoichi Matsuzaki
Jul 29, 2017·Bioscience, Biotechnology, and Biochemistry·Akika FukawaAkira Hosono
Aug 26, 2017·International Journal of Molecular Sciences·Francisco J VizosoRoman Perez-Fernandez
Dec 17, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xueqing Zhong, Hailin Liu

❮ Previous
Next ❯

Citations

Jan 13, 2019·Journal of Cellular and Molecular Medicine·Chenxia HuLanjuan Li
Jul 10, 2019·Stem Cell Research & Therapy·Chenxia HuLanjuan Li
Mar 27, 2020·Frontiers in Pharmacology·Qiongzhen ChenFanghua Gong
Nov 2, 2019·Cells·Daphne PinheiroSimone Carvalho
Aug 15, 2020·Frontiers in Cell and Developmental Biology·Cong WangXuebo Pan
Jan 4, 2021·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Chenxia HuLanjuan Li
Jul 31, 2021·Gastroenterology Research and Practice·Jingguo Li, Biguang Tuo
Oct 3, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Si-Wei XiaShi-Zhong Zheng

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Software Mentioned

SPSS
imageJ
Image Lab

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.